ID

775

Descripción

CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

Link

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

Palabras clave

  1. 26/8/12 26/8/12 -
  2. 8/7/15 8/7/15 -
  3. 8/7/15 8/7/15 -
Subido en

26 de agosto de 2012

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0 Legacy

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Breast Cancer NCT00041119 Eligibility - CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST - 2039130v3.0

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

Unnamed1
Descripción

Unnamed1

CALGB Study No.
Descripción

CALGBProtocolNumber

Tipo de datos

text

CALGB Patient ID
Descripción

CALGBPatientID

Tipo de datos

text

Unnamed2
Descripción

Unnamed2

Patient's Name
Descripción

Patient'sName

Tipo de datos

text

Participating Group
Descripción

ParticipatingGroup

Tipo de datos

text

Alias
NCI Thesaurus ObjectClass
C17005
UMLS 2011AA ObjectClass
C1257890
NCI Thesaurus Property
C25364
UMLS 2011AA Property
C0600091
Patient Hospital Number
Descripción

PatientHospitalNumber

Tipo de datos

text

Participating Group Protocol No.
Descripción

ParticipatingGroupProtocolNo.

Tipo de datos

text

Main Member Institution/Adjunct
Descripción

MainMemberInstitution/Adjunct

Tipo de datos

text

Participating Group Patient No.
Descripción

ParticipatingGroupPatientNo.

Tipo de datos

text

Unnamed3
Descripción

Unnamed3

Histologically confirmed invasive carcinoma of the breast
Descripción

Histologicallyconfirmedinvasivecarcinomaofthebreast

Tipo de datos

text

Undergone either modified radical mastectomy or lumpectomy
Descripción

Undergoneeithermodifiedradicalmastectomyorlumpectomy

Tipo de datos

text

Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
Descripción

NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy

Tipo de datos

text

No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
Descripción

Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer

Tipo de datos

text

No involvement of dermal lymphatics on pathology
Descripción

Noinvolvementofdermallymphaticsonpathology

Tipo de datos

text

"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
Descripción

"High-risk"node-negativebreastcancer

Tipo de datos

text

Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
Descripción

Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative

Tipo de datos

text

No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
Descripción

Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy

Tipo de datos

text

Age >= 18 years
Descripción

Age>=18years

Tipo de datos

text

CTC Performance status 0-1
Descripción

CTCPerformancestatus0-1

Tipo de datos

text

Non-pregnant and non-nursing
Descripción

Non-pregnantandnon-nursing

Tipo de datos

text

No active congestive heart failure nor myocardial infarction within 6 months prior to registration
Descripción

Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration

Tipo de datos

text

Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Descripción

Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix

Tipo de datos

text

Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
Descripción

Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene

Tipo de datos

text

Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
Descripción

Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.

Tipo de datos

text

Date tamoxifen started
Descripción

Datetamoxifenstarted

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Date tamoxifen discontinued
Descripción

Datetamoxifendiscontinued

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Meets ALL of the following laboratory criteria completed within 16 days before registration
Descripción

MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration

Tipo de datos

text

ANC >= 1000/mcL
Descripción

ANC>=1000/mcL

Tipo de datos

text

Date obtained (ANC)
Descripción

Dateobtained(ANC)

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Platelets >= 100,000/mcL
Descripción

Platelets>=100,000/mcL

Tipo de datos

text

Date obtained (Platelets)
Descripción

Dateobtained(Platelets)

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Creatinine <= 2.0 mg/dL
Descripción

Creatinine<=2.0mg/dL

Tipo de datos

text

Date obtained (Creatinine)
Descripción

Dateobtained(Creatinine)

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
Descripción

TotalBilirubin<1.5xupperlimitsofnormaloflaboratory

Tipo de datos

text

Date obtained (Total Bilirubin)
Descripción

Dateobtained(TotalBilirubin)

Tipo de datos

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
ULN (Total Bilirubin)
Descripción

ULN(TotalBilirubin)

Tipo de datos

text

<= 84 days since last major breast surgery
Descripción

<=84dayssincelastmajorbreastsurgery

Tipo de datos

text

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist
Descripción

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Similar models

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Unnamed1
CALGBProtocolNumber
Item
CALGB Study No.
text
CALGBPatientID
Item
CALGB Patient ID
text
Item Group
Unnamed2
Patient'sName
Item
Patient's Name
text
ParticipatingGroup
Item
Participating Group
text
C17005 (NCI Thesaurus ObjectClass)
C1257890 (UMLS 2011AA ObjectClass)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
PatientHospitalNumber
Item
Patient Hospital Number
text
ParticipatingGroupProtocolNo.
Item
Participating Group Protocol No.
text
MainMemberInstitution/Adjunct
Item
Main Member Institution/Adjunct
text
ParticipatingGroupPatientNo.
Item
Participating Group Patient No.
text
Item Group
Unnamed3
Histologicallyconfirmedinvasivecarcinomaofthebreast
Item
Histologically confirmed invasive carcinoma of the breast
text
Undergoneeithermodifiedradicalmastectomyorlumpectomy
Item
Undergone either modified radical mastectomy or lumpectomy
text
NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy
Item
Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
text
Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer
Item
No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
text
Noinvolvementofdermallymphaticsonpathology
Item
No involvement of dermal lymphatics on pathology
text
"High-risk"node-negativebreastcancer
Item
"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
text
Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative
Item
Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
text
Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy
Item
No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
text
Age>=18years
Item
Age >= 18 years
text
CTCPerformancestatus0-1
Item
CTC Performance status 0-1
text
Non-pregnantandnon-nursing
Item
Non-pregnant and non-nursing
text
Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration
Item
No active congestive heart failure nor myocardial infarction within 6 months prior to registration
text
Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix
Item
Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
text
Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene
Item
Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
text
Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.
Item
Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
text
Datetamoxifenstarted
Item
Date tamoxifen started
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Datetamoxifendiscontinued
Item
Date tamoxifen discontinued
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration
Item
Meets ALL of the following laboratory criteria completed within 16 days before registration
text
ANC>=1000/mcL
Item
ANC >= 1000/mcL
text
Dateobtained(ANC)
Item
Date obtained (ANC)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Platelets>=100,000/mcL
Item
Platelets >= 100,000/mcL
text
Dateobtained(Platelets)
Item
Date obtained (Platelets)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Creatinine<=2.0mg/dL
Item
Creatinine <= 2.0 mg/dL
text
Dateobtained(Creatinine)
Item
Date obtained (Creatinine)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
TotalBilirubin<1.5xupperlimitsofnormaloflaboratory
Item
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
text
Dateobtained(TotalBilirubin)
Item
Date obtained (Total Bilirubin)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
ULN(TotalBilirubin)
Item
ULN (Total Bilirubin)
text
<=84dayssincelastmajorbreastsurgery
Item
<= 84 days since last major breast surgery
text
Item Group
Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial